Literature DB >> 3111453

Use of tissue plasminogen activator in experimental hyphema.

F H Lambrou, R W Snyder, G A Williams.   

Abstract

Tissue plasminogen activator (tPA) is a fibrin-specific fibrinolytic agent that has recently been shown to be effective in accelerating the clearance of fibrin clots from the rabbit anterior chamber. We studied the effect of intracameral tPA on the clearance of experimental hyphema in the rabbit. Fifteen eyes were treated with an intracameral injection of tPA (1800 IU), 11 eyes were treated with a physiologic saline solution (PS) injection, and 16 eyes received no injection. Total hyphemas treated with tPA showed 80% clearance within 24 hours, while eyes treated with PS and untreated eyes cleared in 14 days. Measurement of corneal thickness revealed the tPA-treated eyes to have less corneal edema than eyes treated with PS and untreated eyes. There was no difference in intraocular pressure. The results indicate that tPA is effective in accelerating the clearance of experimental hyphema.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111453     DOI: 10.1001/archopht.1987.01060070139044

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.

Authors:  N Baziuk; T Fang; G A Peyman; C M Gremillion
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

3.  Treatment of experimental suprachoroidal hemorrhage with intravenous tissue plasminogen activator.

Authors:  J C Liu; G A Peyman; M Oncel
Journal:  Int Ophthalmol       Date:  1990-07       Impact factor: 2.031

Review 4.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  The use of tissue plasminogen activator in post-traumatic total hyphaema.

Authors:  L Laatikainen; J Mattila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

7.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

8.  Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator.

Authors:  A Szymanski; A Gierek-Lapinska; M Koziak; S Gierek-Kalicka
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

9.  Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage.

Authors:  Nancy Kunjukunju; Christine R Gonzales; William S Rodden
Journal:  Clin Ophthalmol       Date:  2011-02-04

10.  Subconjunctival hemorrhage: risk factors and potential indicators.

Authors:  Bercin Tarlan; Hayyam Kiratli
Journal:  Clin Ophthalmol       Date:  2013-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.